Maryam Nikoonezhad

Dr. Maryam Nikoonezhad


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 November 2022 in Reproductive Sciences
Verified
Journal Article
Closed access
PDF file
ERElham Roshandel
Elham Roshandel
MMMaryam Mehravar
Maryam Mehravar
MNMaryam Nikoonezhad
Maryam Nikoonezhad
AAAfshin Mohammad Alizadeh
Afshin Mohammad Alizadeh
MMMohammad Majidi
Mohammad Majidi
AHAbbas Hajifathali
Abbas Hajifathali

20 December 2024 in Medicine
Verified
Journal Article
Open access
MNMaryam Nikoonezhad
Maryam Nikoonezhad
AHAhmad Zavaran Hosseini
Ahmad Zavaran Hosseini
AHAbbas Hajifathali
Abbas Hajifathali
SPSayeh Parkhideh
Sayeh Parkhideh
MSMahdi Shadnoush
Mahdi Shadnoush
HZHoda Zahedi
Hoda Zahedi
Background: Immune reconstitution is a significant factor in the success of “hematopoietic stem cell transplantation” (HSCT). Delaying the immune reconstitution increases the risk of infections and relapse after transplantation. T-cell recovery after HSCT is mainly thymus-dependent, and thymic atrophy is associated with various clinical conditions that correlate with HSCT outcomes. Thymus rejuvenation can improve immune reconstitution after transplantation. Zinc (Zn) plays a pivotal role in thymus rejuvenation. Zn deficiency can lead to thymic atrophy, which increases susceptibility to infections. Zn supplementation restores the immune system by increasing thymus output and T-cell repertoire production. We designed this protocol to investigate the effect of oral Zn supplementation on T-cell recovery in patients undergoing HSCT. Methods: Forty eligible candidates for autologous-HSCT will be selected. They will be randomly divided into Zn and placebo groups. Subsequently, they will receive 3 Zn or placebo tablets for the first 30 days post-HSCT (+1 to +30), followed by 1 pill or placebo for days (+31 to +90). The copy numbers of “recent thymic emigrants” T cells and “T cell Receptor Excision Circles” (TREC) will be assessed before and after the intervention in peripheral blood mononuclear cells (PBMCs). All patients will be followed up 365 days post-HSCT for relapse and infection. Conclusion: This clinical trial is the first to determine the efficiency of “Zn gluconate” as daily Supplementation in T cell recovery post-HSCT. If successful, an available and inexpensive drug will improve immune system reconstruction after HSCT, reduce the risk of infection, particularly viral infections, and increase patient survival.

18 May 2025 in International Journal of Cancer Management
Verified
Journal Article
Open access
MGMahmoud Dehghani Ghorbi
Mahmoud Dehghani Ghorbi
ERElham Roshandel
Elham Roshandel
MNMaryam Nikoonezhad
Maryam Nikoonezhad
ASAnahita Saeedi
Anahita Saeedi
MVMahshid Vafajoo
Mahshid Vafajoo
MMMahshid Mehdizadeh
Mahshid Mehdizadeh
Background: Thrombocytopenia is a primary consequence of chemotherapy and radiotherapy in leukemia, leading to the need for blood product transfusions in patients undergoing hematopoietic stem cell transplantation (HSCT). Although blood product transfusion plays a pivotal role in the supportive care of HSCT patients, multiple transfusions can lead to alloreactive complications. Objectives: In this study, we assessed the association of pre-transplant platelet count and blood product transfusions with acute graft-versus-host disease (aGVHD), organ failure, and overall survival (OS) as outcomes following HSCT. Methods: This retrospective study was conducted on clinical records of 184 patients who underwent allogeneic HSCT (allo-HSCT). Platelet counts on admission and on the day of transplantation were analyzed using ROC analysis to determine cut-off values. The associations between platelet count, packed red cell volume, and platelet transfusions with aGVHD, organ failure, and OS were examined. Results: A platelet count >134.5×103/µL on the day of transplantation was associated with a 56% reduction in the risk of mortality (P = 0.045). An increased number of random donor platelet transfusions had a significant adverse effect on aGVHD incidence and 5-year OS (P = 0.228, 0.035). The number of packed cell units transfused was significantly associated with both increased odds of aGVHD incidence and a higher risk of mortality (P = 0.041, < 0.001). Conclusions: Pre-transplantation platelet count and blood product transfusion are associated with a higher risk of aGVHD and reduced 5-year OS following allo-HSCT. Therefore, implementing strategies to minimize blood product transfusion may help reduce the incidence of aGVHD and improve overall survival.

14 August 2025 in Indian Journal of Hematology and Blood Transfusion
Verified
Journal Article
Closed access
PDF file
MNMaryam Nikoonezhad
Maryam Nikoonezhad
SPSahar Parkhideh
Sahar Parkhideh
EZErfan Zamani
Erfan Zamani
MGMahdi Gholamian
Mahdi Gholamian
SPSayeh Parkhideh
Sayeh Parkhideh
AHAbbas Hajifathali
Abbas Hajifathali